Trial Profile
Understanding the Interaction Between Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Darolutamide (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 13 Feb 2023 Status changed from not yet recruiting to recruiting.
- 18 Jan 2023 New trial record